Skip to content

To analyze real-world data of abrocitinib in the treatment of adolescents with moderate-to-severe atopic dermatitis (AD) in Guangzhou, China

To analyze real-world data of abrocitinib in the treatment of adolescents with moderate-to-severe atopic dermatitis (AD) in Guangzhou, China

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097613
Enrollment
Unknown
Registered
2025-02-21
Start date
2025-01-16
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Abuxitinib treatment group:None

Sponsors

Guangzhou Dermatology Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 17 Years

Inclusion criteria

Inclusion criteria: (1) Age between 12-17 years old; (2) The diagnosis of AD was confirmed by two professional dermatologists, and the diagnostic criteria were based on Williams criteria (determining diagnosis: primary criteria+3 or more secondary criteria). ·Main diagnostic criteria: Symptoms of skin itching; ·Secondary diagnostic criteria: History of involvement on the flexed side, including the elbow fossa, popliteal fossa, ankle anterior, and neck; History of asthma or allergic rhinitis; In recent years, there has been a history of dry skin throughout the body; Eczema on the flexed side; Onset before the age of 2; (3) The patient did not use traditional immunosuppressants, small molecule targeted drugs, or biologics within the first 3 months of enrollment; (4) During screening, the severity of AD in patients met the criteria of EASI >= 16 SCORAD>=25IGA>=3,Itch/sleep-NRS>=4.

Exclusion criteria

Exclusion criteria: (1) Severe infection (active tuberculosis, hepatitis B, HIV infection, etc.); (2) Those who are currently receiving or preparing to receive live or attenuated vaccines; (3) Immunocompromised individuals; (4) Individuals who are allergic to Abu Xitinib and any drug ingredients it contains; (5) Other systemic diseases or active skin diseases (such as psoriasis or lupus erythematosus) that may affect AD or research results exist; (6) Significant abnormalities in heart, liver, and kidney function results that affect the medication user; (7) Researchers consider participants who are uncooperative or unable to follow the research process.

Design outcomes

Primary

MeasureTime frame
clinical efficacy score;

Secondary

MeasureTime frame
cytokine;total IgE;

Countries

China

Contacts

Public ContactXibao Zhang

Guangzhou Dermatology Hospital

gzpfbfzs@163.com+86 139 0305 9916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026